Eisai Inc., of Teaneck, N.J., appointed Louis Arp vice president of production operations, and Lyn Olson vice president of quality, both at the Research Triangle Park, N.C., facility.
Enzon Pharmaceuticals Inc., of Bridgewater, N.J., appointed Robert Salisbury to its board and audit committee.
Eximias Pharmaceutical Corp., of Berwyn, Pa., appointed Ruedi Waeger to its board.
Forest Laboratories Inc., of New York, promoted Ivan Gergel to senior vice president of scientific affairs and president of the Forest Research Institute.
Galapagos NV, of Mechelen, Belgium, appointed Ferdinand Verdonck independent director, and Harrold van Barlinger dependent director.
GammaCan International Inc., of Givat Shmuel, Israel, appointed Yosef Yarden to the scientific advisory board.
Genmab A/S, of Copenhagen, Denmark, appointed Annarie Lyles vice president, business development.
GTx Inc., of Memphis, Tenn., appointed Robert Karr to its board.
Idenix Pharmaceuticals Inc., of Cambridge, Mass., appointed Pamela Thomas-Graham to its board.
Immusol Inc., of San Diego, appointed Barry Simon vice president of clinical and regulatory affairs, and Zhu Shen director of business development.
Ingenium Pharmaceuticals AG, of Munich, Germany, appointed Michael Grau chief financial officer.
Inhibitex Inc., of Atlanta, appointed Keith Willard to its board.
Intec Pharma, of Jerusalem, appointed Efi Cohen Arazi CEO.